Foaming drug efficacy-imparting composition, aerosol product, and foaming fragrance deodorizing composition

Abstract

To provide a foaming drug efficacy-imparting composition to be packed in a spray product, which exhibits excellent diffusibility of an active ingredient without increasing foam retention, is capable of exerting excellent drug efficacy, and also provides a superior use feeling.SOLUTION FOR THE PROBLEM: In a foaming drug efficacy-imparting composition to be packed in a spray product, the composition comprises (A) an active ingredient, (B) a surfactant, (C) an organic solvent, and water. When the composition is sprayed for one second into a 300-mL measuring cylinder having a bottom area of 11.3 cm2, a foam volume ratio, which is the ratio of a maximum value X of a foam volume immediately after spraying to a foam volume Y one minute after spraying, is Y / X≤0.99.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present invention relates to a foamable medicinal composition and a medicinal method using the same. [Background technology]

[0002] Many foaming products have a pleasant feel when used because the foam appearance can be seen. For this reason, various types of foaming products have been studied and developed.

[0003] For example, Patent Document 1 describes a foaming aerosol composition for deodorization that can form foam that does not defoam or dry for a long time, and that can remain on the surface of a malodor source for a long time without drying, thereby covering the malodor source with the foam and preventing the malodor from diffusing into the air. Also, Patent Document 2 describes a foaming aerosol composition that is sprayed as a concentrate and has good foam-forming properties even at room temperature or low temperature, and is easy to use because of its excellent foam-forming properties and durability.

[0004] However, the aerosol compositions described in Patent Documents 1 and 2 are both designed to increase the persistence of foam after foaming, and it is believed that increasing the persistence of foam extends the exposure time to the target object, allowing the composition to fully demonstrate its performance. Furthermore, it has been thought that an aerosol composition with poor foam persistence may be unable to fully demonstrate its performance due to the shortened exposure time to the target object. Therefore, there has been a demand for an aerosol composition that can demonstrate excellent medicinal efficacy without increasing the persistence of foam. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] Japanese Patent Application Publication No. 11-206868 [Patent Document 2] Japanese Patent Application Publication No. 2019-210302 Summary of the Invention [Problem to be solved by the invention]

[0006] The present invention has been made in consideration of the above problems, and aims to provide a foamable medicinal effect-imparting composition to be filled into a spray product, which exhibits excellent diffusibility of the active ingredient, can exert excellent medicinal effects, and has an excellent feel when used, without increasing the foam persistence. [Means for solving the problem]

[0007] As a result of extensive research conducted by the inventors in order to achieve the object of the present invention, they discovered that in a foamable medicinal effect-imparting composition to be filled into a spray product, it is important for the foam volume ratio, which is the rate of change in foam volume after spraying, to be within a specific range in order to improve the diffusibility of the active ingredient, medicinal effect, and usability, and thus completed the present invention.

[0008] The present invention has found that the following configurations are highly effective in achieving the above-mentioned object. (1) A foamable medicinal composition for filling a spray product, comprising: The composition contains (A) an active ingredient, (B) a surfactant, (C) an organic solvent, and water; The composition was placed in a container with a base area of ​​11.3 cm 2 When sprayed for 1 second into a 300 mL measuring cylinder, the foam volume ratio, which is the ratio of the maximum foam volume X immediately after spraying to the foam volume Y 1 minute after spraying, is Y / X≦0.99. (2) The foamable medicinal effect-imparting composition according to (1), wherein the (C) organic solvent is one or more selected from the group consisting of hydrocarbon solvents, alcohol solvents, and glycol solvents. (3) The foamable medicinal effect-imparting composition according to (1) or (2), wherein the (C) organic solvent is blended in an amount of 0.5 to 30% by mass. (4) The foamable medicinal effect-imparting composition according to any one of (1) to (3), wherein the weight ratio of the (A) active ingredient to the (C) organic solvent is 10≦(C) / (A)≦700. (5) The foamable medicinal effect-imparting composition according to any one of (1) to (4), wherein the ratio Y / X is Y / X≦0.70. (6) The effervescent medicinal effect-imparting composition according to any one of (1) to (5), wherein the pH of the composition is 5.0 to 12.0. (7) The foaming medicinal effect-imparting composition according to any one of (1) to (6), wherein the surfactant is a nonionic surfactant and / or an amphoteric surfactant. (8) The foaming medicinal effect-imparting composition according to any one of (1) to (7), wherein the (A) active ingredient is a deodorizing aromatic ingredient, and the medicinal effect is a deodorizing aromatic effect. (9) The foaming medicinal effect-imparting composition according to any one of (1) to (7), wherein the (A) active ingredient is an antifouling ingredient and the medicinal effect is an antifouling effect. (10) The foaming medicinal effect-imparting composition according to any one of (1) to (7), wherein the (A) active ingredient is an antifungal ingredient and the medicinal effect is an antifungal effect. (11) An aerosol product obtained by filling the composition according to any one of (1) to (10) above and a propellant into an aerosol container. (12) A spray product obtained by filling the composition according to any one of (1) to (10) above into a spray container. (13) A foamable medicinal effect-imparting composition comprising (A) an active ingredient, (B) a surfactant, (C) an organic solvent, and water, The composition was placed in a container with a base area of ​​11.3 cm 2 The foam volume ratio, which is the ratio of the maximum foam volume X immediately after spraying to the foam volume Y one minute after spraying, when sprayed for one second into a 300 mL measuring cylinder, is Y / X≦0.99. [Effects of the Invention]

[0009] The foamable medicinal effect-imparting composition of the present invention has excellent diffusibility of the active ingredient, can exert excellent medicinal effects, and has an excellent feel when used, even without increasing the foam persistence. In particular, when the active ingredient is a deodorizing ingredient, an antifouling ingredient, or an antifungal ingredient, the diffusibility is excellent, an excellent deodorizing effect can be exerted, and the feel when used is excellent. Therefore, the composition is suitable for use in places where bad odors are a problem, such as toilets, drains, and washing machine drums, and is extremely practical. DETAILED DESCRIPTION OF THE INVENTION

[0010] The effervescent medicinal effect-imparting composition of the present invention and the medicinal effect-imparting method using the same will be described in detail below. However, the present invention is not intended to be limited to the configurations described in the following embodiments and examples. In this specification, the symbol "to" includes a boundary value.

[0011] The active ingredient (A) used in the present invention is not particularly limited, but examples thereof include deodorizing aromatic ingredients, antifungal ingredients, insect repellent ingredients, antifouling ingredients, antislime ingredients, antibacterial ingredients, virus inactivating ingredients, etc. One or more of these ingredients may be used.

[0012] The deodorizing aromatic component is not particularly limited, and may be, for example, a component that masks malodors or a component that changes the scent to a pleasant one by harmonizing the scent, such as a fragrance or essential oil. Examples of fragrances include hydrocarbon fragrances such as limonene such as d-limonene, pinene such as α-pinene and β-pinene, cymene such as p-cymene, indene, and caryophyllene, menthol such as linalool, geraniol, citronellol, and l-menthol, ethyl linalool, borneol, anise alcohol, β-phenethyl alcohol, p-menthane-3,8-diol, terpineol such as α-terpineol and γ-terpineol, 1-hexenol, cis-3-hexen-1-ol, tetrahydrogeraniol, and san. Alcohol-based fragrances such as talinol, cinnamyl alcohol, cedrol, etc.; cineoles such as caraxolide, β-naphthyl methyl ether, 1,4-cineole, 1,8-cineole, etc.; ether-based fragrances such as ambroxide, p-cresyl methyl ether, etc.; phenol-based fragrances such as anethole, eugenol, isoeugenol, vanillin, ethyl vanillin, etc.; octanal, nonanal, undecyl aldehyde, undecanal, decyl aldehyde, n-butyraldehyde, isobutyraldehyde, hexyl aldehyde, citral, etc. Aldehyde fragrances such as toral, citronellal, benzaldehyde, cinnamic aldehyde, anisaldehyde, cuminaldehyde, adoxal, amyl cinnamic aldehyde, and cyclamen aldehyde, musk ketone, carvone, menthone, camphor, camphor, acetophenone, butyrophenone, tonalide, α-ionone, β-ionone, α-methyl ionone, β-methyl ionone, α-isomethyl ionone, β-isomethyl ionone, γ-methyl ionone, γ-isomethyl ionone, damascone, α-da Ketone fragrances such as mascone, β-damascone, acetyl cedrene, cashmeran, cis-jasmone, and dihydrojasmone; lactone fragrances such as γ-butyrolactone, γ-nonalactone, γ-decalactone, γ-undecalactone, coumarin, cineole, ambrosia lid, and jasmolactone; geranyl formate, octyl acetate, geranyl acetate, benzyl acetate, cinnamyl acetate, tetrahydrogeranyl acetate, menthyl acetate, linalyl acetate, butyl propionate, and benzyl acetate.Methyl benzoate, allyl hexanoate, allyl heptanoate, allyl cyclohexane propionate, allyl amyl glycolate, amyl valerianate, amyl salicylate, isoamyl acetate, butyl acetate, ethyl butyrate, acetyl eugenol, isoamyl salicylate, allyl caproate, ethyl caproate, ethyl propionate, ethyl acetoacetate, methyl salicylate, citronellyl acetate, citronellol Examples of suitable fragrances include ester-based fragrances such as methyl formate, cinnamyl acetate, stearyl acetate, stearyl propionate, cedryl acetate, and terpinyl acetate; acetal-based fragrances such as amyl cinnamic aldehyde dimethyl acetal and citral dimethyl acetal; indole, geranyl nitrile, citronellyl nitrile, acetaldehyde phenylethyl propyl acetate, thesalon, auranthiol, and linalool oxide. The fragrances listed above can be used alone, or blended fragrances containing two or more types can also be used. These are known as synthetic fragrances or extracted fragrances.

[0013] Examples of essential oils include peppermint oil, orange oil, lemon oil, lavender oil, peppermint oil, eucalyptus oil, citronella oil, lime oil, yuzu oil, jasmine oil, cypress oil, green tea essential oil, neroli oil, geranium oil, petitgrain oil, lemongrass oil, cinnamon oil, lemon eucalyptus oil, thyme oil, perilla oil, petitgrain oil, pine oil, rose oil, rosemary oil, camphor oil, aromatic oils, clary sage oil, sandalwood oil, spearmint oil, star anise oil, lavandin oil, oakmoss oil, ocotia oil, patchouli oil, tonka bean tincture, turpentine oil, crocus bean tincture, basil oil, nutmeg oil, clove oil, and bois draw. Examples of essential oils include laurel oil, cananga oil, cardamom oil, cassia oil, cedarwood oil, mandarin oil, tangerine oil, anise oil, bay oil, coriander oil, elemi oil, fennel oil, galbanum oil, hiba oil, cypress oil, vetiver oil, bergamot oil, ylang-ylang oil, grapefruit oil, abies oil, accion oil, almond oil, angelica root oil, peper oil, mint oil, perch oil, boswellia oil, kayabuchi oil, gananga oil, capsicum oil, caraway oil, celery oil, cognac oil, cumin oil, jill oil, estgolan oil, garlic oil, ginger oil, hop oil, sage oil, and turpentine oil. The above-mentioned essential oils can be used alone, or a mixture of two or more of the above-mentioned essential oils can also be used.

[0014] The antifungal component is not particularly limited, but examples thereof include phenolic antifungal components such as isopropylmethylphenol (IPMP), carvacrol, thymol, triclosan, methylparaben, ethylparaben, propylparaben, butylparaben, 4-chloro-3,5-dimethylphenol, orthophenylphenol, o-cresol, m-cresol, and p-cresol; benzalkonium salts such as benzalkonium chloride, benzalkonium methosulfate, and benzalkonium organic acid salts; benzethonium chloride; and benzethonium. benzethonium salts such as methosulfate and benzethonium organic acid salts, cetylpyridinium salts such as cetylpyridinium chloride, cetylpyridinium methosulfate and cetylpyridinium organic acid salts, didecyldimethylammonium salts such as didecyldimethylammonium chloride and decyldimethylammonium methosulfate, dilauryldimethylammonium salts such as dilauryldimethylammonium chloride and dilauryldimethylammonium methosulfate, distearyldimethylammonium chloride, distearyldimethylammonium Distearyldimethylammonium salts such as ammonium methosulfate, and cationic surfactant antifungal ingredients such as 1,4-bis[3,3'-(1-decylpyridinium)methyloxy]butane dibromide, 1,4-bis[3,3'-(1-decylpyridinium)methyloxy]butane dichloride, 1,4-bis[3,3'-(1-decylpyridinium)methyloxy]butane dimethosulfate and other 1,4-bis[3,3'-(1-decylpyridinium)methyloxy]butane salts, biguanide antifungal ingredients, tebuconazole, enilconazole Azole-based antifungal ingredients such as azole, fruit seed extract-based antifungal ingredients such as grapefruit seed extract, persimmon seed extract, and grape seed extract, glycerin mono fatty acid ester-based antifungal ingredients such as monolaurin, monocaprin, and monocaprylin, chlorhexidine salts such as chlorhexidine gluconate and chlorhexidine dihydrochloride, and chlorhexidine-based antifungal ingredients such as chlorhexidine, octadecyldimethyl(3-triethoxysilylpropyl)ammonium chloride, dodecyldimethyl(3-triethoxysilylpropyl)ammonium chloride,Dodecyldiisopropyl(3-triethoxysilylpropyl)ammonium chloride, tetradecyldimethyl(3-triethoxysilylpropyl)ammonium chloride, tetradecyldiethyl(3-triethoxysilylpropyl)ammonium chloride, tetradecyldi-n-propyl(3-triethoxysilylpropyl)ammonium chloride, pentadecyldimethyl(3-triethoxysilylpropyl)ammonium chloride, pentadecyldiethyl(3-triethoxysilylpropyl)ammonium chloride, pentadecyldi-n-propyl(3-triethoxysilylpropyl)ammonium chloride, hexadecyldimethyl(3-triethoxysilylpropyl)ammonium chloride, hexadecyldiethyl(3-triethoxysilylpropyl)ammonium chloride Silicon-based antifungal ingredients such as hexadecyldi-n-propyl(3-triethoxysilylpropyl)ammonium chloride, octadecyldiethyl(3-triethoxysilylpropyl)ammonium chloride, and octadecyldi-n-propyl(3-triethoxysilylpropyl)ammonium chloride; carboxylic acid-based antifungal ingredients such as benzoic acid, salicylic acid, sorbic acid, ethylenediaminetetraacetic acid (EDTA), glycine, alkyldiethylaminoglycine, and polylysine, or salts thereof; and silver-based antifungal ingredients such as dehydroacetic acid, chloramine, 3-iodo-2-propyl-N-butylcarbamate (IPBC), phenoxyethanol, and silver zeolite; zinc pyrithione, thiamine lauryl sulfate, milt protein, hydroxyalkyl chitosan or its salt, and antifungal fragrances. The above antifungal ingredients can be used alone, or a mixture of two or more of the above antifungal ingredients can also be used.

[0015] The insect repellent component is not particularly limited, but examples thereof include pyrethroid insect repellent components such as fenothrin, etofenprox, silafluofen, permethrin, cypermethrin, transfluthrin, metofluthrin, profluthrin, empenthrin, cyfluthrin, cyphenothrin, allethrin, prallethrin, phthalthrin, imiprothrin, momfluorothrin, mepafluthrin, heptafluthrin, tefluthrin, resmethrin, furamethrin, pyrethrins, acrinathrin, bifenthrin, deltamethrin, and tetramethrin; neonicotinoid insect repellent components such as dinotefuran, imidacloprid, and clothianidin; brofuranilide, DEET, icaridin, ethyl butylacetylaminopropionate (IR3535), p-menthane-3,8-diol, menthyl acetate, and peppermint oil. The above insect repellent components can be used alone, or a mixture of two or more of the above insect repellent components can also be used.

[0016] The stain-resistant component is not particularly limited, but examples thereof include alkyl glycoside stain-resistant components such as octyl glucoside, decyl glucoside, lauryl glucoside, myristyl glucoside, and cetyl glucoside; quaternary ammonium salt stain-resistant components such as cetylpyridinium chloride, benzalkonium chloride, benzethonium chloride, cetyltrimethylammonium chloride, stearyltrimethylammonium chloride, distearyldimethylammonium chloride, dimyristyldimethylammonium chloride, dimyristyldimethylammonium methylsulfate, and didecyldimethylammonium methosulfate; dimethyldiallylammonium chloride homopolymers such as dimethyldiallylammonium chloride; Examples of suitable antifouling components include quaternary ammonium salt polymer-based antifouling components such as copolymers of quaternary ammonium salts such as dimethyldiallylammonium chloride with acrylamide, acrylic acid, acrylic acid salts, and other acrylic acid derivatives, α-perfluorononenyloxy-ω-methylpolyethylene oxide, fluorinated alkyl hydrophilic group-containing oligomers, fluorinated alkyl ester addition polymers, fluorine-substituted glycols such as partially fluorinated alcohol-substituted glycols, alkylene oxide adducts of acetylene glycol, polyether-modified polysiloxanes, ethylenediaminetetraacetic acid and its salts, nitrilotriacetic acid and its salts, gluconic acid and its salts, etc. The above antifouling components can be used alone, or a mixture of two or more of the above antifouling components can be used.

[0017] The anti-sliming component is not particularly limited, but examples thereof include allyl isothiocyanate, trichloroisocyanuric acid, etc. The anti-sliming component may be used alone, or a mixture of two or more of the anti-sliming components may also be used.

[0018] The antibacterial component is not particularly limited, but examples thereof include phenolic antibacterial components such as isopropylmethylphenol (IPMP), carvacrol, thymol, triclosan, methylparaben, ethylparaben, propylparaben, butylparaben, 4-chloro-3,5-dimethylphenol, orthophenylphenol, o-cresol, m-cresol, and p-cresol; benzalkonium salts such as benzalkonium chloride, benzalkonium methosulfate, and benzalkonium organic acid salts; benzethonium chloride; and benzethonium. Benzethonium salts such as methosulfate and benzethonium organic acid salts, cetylpyridinium salts such as cetylpyridinium chloride, cetylpyridinium methosulfate and cetylpyridinium organic acid salts, didecyldimethylammonium salts such as didecyldimethylammonium chloride and decyldimethylammonium methosulfate, dilauryldimethylammonium salts such as dilauryldimethylammonium chloride and dilauryldimethylammonium methosulfate, distearyldimethylammonium chloride, distearyldimethylammonium chloride cationic surfactant-based antibacterial ingredients such as distearyldimethylammonium salts such as ammonium methosulfate, and 1,4-bis[3,3'-(1-decylpyridinium)methyloxy]butane salts such as 1,4-bis[3,3'-(1-decylpyridinium)methyloxy]butane dibromide, 1,4-bis[3,3'-(1-decylpyridinium)methyloxy]butane dichloride, and 1,4-bis[3,3'-(1-decylpyridinium)methyloxy]butane dimethosulfate; biguanide-based antibacterial ingredients; tebuconazole; enyl Azole antibacterial ingredients such as conazole, fruit seed extract antibacterial ingredients such as grapefruit seed extract, persimmon seed extract, grape seed extract, etc., glycerin mono fatty acid ester antibacterial ingredients such as monolaurin, monocaprin, monocaprylin, etc., chlorhexidine salts such as chlorhexidine gluconate and chlorhexidine dihydrochloride, chlorhexidine antibacterial ingredients such as chlorhexidine, octadecyldimethyl(3-triethoxysilylpropyl)ammonium chloride, dodecyldimethyl(3-triethoxysilylpropyl)ammonium chloride,Dodecyldiisopropyl(3-triethoxysilylpropyl)ammonium chloride, tetradecyldimethyl(3-triethoxysilylpropyl)ammonium chloride, tetradecyldiethyl(3-triethoxysilylpropyl)ammonium chloride, tetradecyldi-n-propyl(3-triethoxysilylpropyl)ammonium chloride, pentadecyldimethyl(3-triethoxysilylpropyl)ammonium chloride, pentadecyldiethyl(3-triethoxysilylpropyl)ammonium chloride, pentadecyldi-n-propyl(3-triethoxysilylpropyl)ammonium chloride, hexadecyldimethyl(3-triethoxysilylpropyl)ammonium chloride, hexadecyldiethyl(3-triethoxysilylpropyl)ammonium Examples of antibacterial agents include silicon-based antibacterial agents such as ammonium chloride, hexadecyldi-n-propyl(3-triethoxysilylpropyl)ammonium chloride, octadecyldiethyl(3-triethoxysilylpropyl)ammonium chloride, and octadecyldi-n-propyl(3-triethoxysilylpropyl)ammonium chloride; carboxylic acid-based antibacterial agents such as benzoic acid, salicylic acid, sorbic acid, ethylenediaminetetraacetic acid (EDTA), glycine, alkyldiethylaminoglycine, and polylysine, or salts thereof; dehydroacetic acid, chloramine, 3-iodo-2-propyl-N-butylcarbamate (IPBC), phenoxyethanol, and silver-based antibacterial agents such as silver zeolite; zinc pyrithione, thiamine lauryl sulfate, milt protein, and hydroxyalkylchitosan or salts thereof. The above antibacterial agents can be used alone, or a mixture of two or more of the above antibacterial agents can also be used.

[0019] The virus inactivating component is not particularly limited, but examples thereof include phenolic virus inactivating components such as isopropylmethylphenol (IPMP), carvacrol, thymol, triclosan, methylparaben, ethylparaben, propylparaben, butylparaben, 4-chloro-3,5-dimethylphenol, orthophenylphenol, o-cresol, m-cresol, and p-cresol; benzalkonium salts such as benzalkonium chloride, benzalkonium methosulfate, and benzalkonium organic acid salts; benzethonium salts such as benzethonium chloride, benzethonium methosulfate, and benzethonium organic acid salts; cetylpyridinium salts such as cetylpyridinium chloride, cetylpyridinium methosulfate, and cetylpyridinium organic acid salts; didecyldimethylammonium salts such as didecyldimethylammonium chloride and decyldimethylammonium methosulfate; dilauryldimethylammonium salts such as dilauryldimethylammonium chloride and dilauryldimethylammonium methosulfate; distearyldimethylammonium chloride; cationic surfactant-based virus inactivating ingredients such as distearyldimethylammonium salts such as tearyldimethylammonium methosulfate, and 1,4-bis[3,3'-(1-decylpyridinium)methyloxy]butane salts such as 1,4-bis[3,3'-(1-decylpyridinium)methyloxy]butane dibromide, 1,4-bis[3,3'-(1-decylpyridinium)methyloxy]butane dichloride, and 1,4-bis[3,3'-(1-decylpyridinium)methyloxy]butane dimethosulfate; biguanide-based virus inactivating ingredients activating ingredients, azole virus inactivating ingredients such as tebuconazole and enilconazole, fruit seed extract virus inactivating ingredients such as grapefruit seed extract, persimmon seed extract and grape seed extract, glycerin mono fatty acid ester virus inactivating ingredients such as monolaurin, monocaprin and monocaprylin, chlorhexidine salts such as chlorhexidine gluconate and chlorhexidine hydrochloride, chlorhexidine virus inactivating ingredients such as chlorhexidine, octadecyldimethyl(3-triethoxysilylpropyl)ammonium chloride,Dodecyldimethyl(3-triethoxysilylpropyl)ammonium chloride, dodecyldiisopropyl(3-triethoxysilylpropyl)ammonium chloride, tetradecyldimethyl(3-triethoxysilylpropyl)ammonium chloride, tetradecyldiethyl(3-triethoxysilylpropyl)ammonium chloride, tetradecyldi-n-propyl(3-triethoxysilylpropyl)ammonium chloride, pentadecyldimethyl(3-triethoxysilylpropyl)ammonium chloride, pentadecyldiethyl(3-triethoxysilylpropyl)ammonium chloride, pentadecyldi-n-propyl(3-triethoxysilylpropyl)ammonium chloride, hexadecyldimethyl(3-triethoxysilylpropyl)ammonium chloride, hexadecyldiethyl(3-triethoxysilylpropyl)ammonium chloride Examples of virus inactivating components include silicon-based virus inactivating components such as hexadecyldi-n-propyl(3-triethoxysilylpropyl)ammonium chloride, hexadecyldi-n-propyl(3-triethoxysilylpropyl)ammonium chloride, octadecyldiethyl(3-triethoxysilylpropyl)ammonium chloride, and octadecyldi-n-propyl(3-triethoxysilylpropyl)ammonium chloride; carboxylic acid-based virus inactivating components such as benzoic acid, salicylic acid, sorbic acid, ethylenediaminetetraacetic acid (EDTA), glycine, alkyldiethylaminoglycine, and polylysine, or salts thereof; silver-based virus inactivating components such as dehydroacetic acid, chloramine, 3-iodo-2-propyl-N-butylcarbamate (IPBC), phenoxyethanol, and silver zeolite; zinc pyrithione, thiamine lauryl sulfate, milt protein, and hydroxyalkyl chitosan or salts thereof. The above virus inactivating components can be used alone, or a mixture of two or more of the above virus inactivating components can also be used.

[0020] The blending amount of component (A) in the foamable medicinal effect-imparting composition is preferably 0.01 to 10 mass %, more preferably 0.02 to 5 mass %, and even more preferably 0.05 to 2 mass %.

[0021] The surfactant (B) used in the present invention may be any of anionic surfactants, nonionic surfactants, and amphoteric surfactants. Examples of the anionic surfactants include alkylbenzene sulfonates, linear alkylbenzene sulfonates, alkyl sulfates, α-olefin sulfonates, alkyl phosphate esters, polyoxyethylene alkyl ether sulfates, polyoxyethylene alkylphenyl ether sulfates, and polyoxyethylene alkyl ether phosphates. Examples of the nonionic surfactants include polyoxyethylene alkyl ethers such as polyoxyethylene oleyl ether, polyoxyethylene tridecyl ether, polyoxyethylene cetyl ether, and polyoxyethylene 2-ethylhexyl ether; polyoxyethylene polyoxypropylene cetyl ether and polyoxyethylene polyoxypropylene 2-ethylhexyl ether; Examples of surfactants include oxyethylene polyoxypropylene alkyl ethers, polyoxyethylene alkylphenyl ethers, polyoxyethylene higher fatty acid esters, polyoxyethylene glycerin fatty acid esters, polyoxyethylene sorbitan fatty acid esters, fatty acid alkanolamides, alkyl polyglucosides such as lauryl polyglucosides and myristyl polyglucosides, coconut oil fatty acid diethanolamides, and polyoxyethylene hydrogenated castor oil. Examples of amphoteric surfactants include alkylamine oxides, coconut oil alkyl dimethylamine oxides, aminoacetic acid betaine, amidopropyl betaine, alkylamidopropyl hydroxysultaine, and 2-alkyl-N-carboxymethyl-N-hydroxyethyl imidazolinium betaine. Among these surfactants, from the viewpoint of foaming ability, it is preferable to contain a nonionic surfactant and / or an amphoteric surfactant, more preferably a nonionic surfactant, even more preferably a polyoxyethylene alkyl ether and / or polyoxyethylene polyoxypropylene alkyl ether, and even more preferably a polyoxyethylene alkyl ether and / or polyoxyethylene polyoxypropylene alkyl ether having a branched alkyl chain. These surfactants can be used alone or in combination.The foamable medicinal effect-imparting composition of the present invention preferably contains 0.1 to 10% by mass of (B) surfactant. Note that, in this specification, cationic surfactants that are antifungal, antibacterial, antifouling, or virus inactivating components are not considered to be (B) surfactants.

[0022] The solvent (C) used in the present invention is not particularly limited, and examples thereof include hydrocarbon solvents such as normal paraffin, isoparaffin, liquid paraffin, naphthenic hydrocarbons, petrolatum, squalane, α-olefin oligomers, and squalane; alcohol solvents such as ethanol, 1-propanol, 2-propanol (IPA), 1-butanol, 2-butanol, tertiary butanol, 1-pentanol, 1-hexanol, benzyl alcohol, and 2-phenylethanol; and glycol solvents such as 2-phenoxyethanol (ethylene glycol monophenyl ether), ethylene glycol, propylene glycol, 1-phenoxy-2-propanol (propylene glycol phenyl ether), 1,3-butylene glycol, propylene glycol monobutyl ether, dipropylene glycol monobutyl ether, and tripropylene glycol monobutyl ether. One or more of these solvents can be used in combination, and the solvent (C) is preferably blended in an amount of 0.5 to 30% by mass in the foamable medicinal effect-imparting composition of the present invention.

[0023] Examples of water used in the present invention include purified water such as ion-exchanged water and reverse osmosis water, as well as ordinary tap water, industrial water, deep sea water, etc. The amount of water to be added is not particularly limited as long as solubility is maintained, but it is preferable that the amount of water added to the effervescent medicinal effect-imparting composition of the present invention be 50 to 99% by mass.

[0024] Furthermore, the foaming medicinal effect-imparting composition of the present invention may contain other ingredients, such as algae inhibitors, chelating agents such as sodium citrate, pH adjusters such as citric acid, rust inhibitors such as sodium benzoate, pigments such as blue pigments, green pigments, and red pigments, antifouling agents, etc., as needed, within the range that does not impair the effects of the present invention.

[0025] In the present invention, the effervescent medicinal composition is placed in a container having a base area of ​​11.3 cm 2 When the foamable medicinal effect-imparting composition of the present invention is sprayed for 1 second into a 300 mL measuring cylinder, the foam volume ratio, which is the ratio of the maximum foam volume X immediately after spraying to the foam volume Y 1 minute after spraying, is preferably Y / X≦0.99, more preferably Y / X≦0.70. When the foamable medicinal effect-imparting composition of the present invention is sprayed, and the foam volume ratio, which is the rate of change in foam volume, is within the above range, the diffusibility of the active ingredient is improved, and excellent medicinal effects can be exhibited.

[0026] The blending mass ratio of (A) the active ingredient to (C) the organic solvent in the foamable medicinal effect-imparting composition of the present invention is preferably 10≦(C) / (A)≦700, and more preferably 50≦(C) / (A)≦500. When (C) / (A) is within the above range, the diffusibility of the active ingredient is improved, and excellent medicinal effects can be exhibited.

[0027] The pH of the effervescent medicinal effect-imparting composition of the present invention is preferably 5.0 to 12.0, which makes it weakly acidic to basic and allows it to be used on metals that are easily corroded by strong acids, making it a highly versatile effervescent medicinal effect-imparting composition.

[0028] The efficacy of the foamable medicinal effect-imparting composition of the present invention varies depending on the active ingredient (A). For example, if the component (A) is a deodorizing component, it will have a deodorizing effect; if the component (A) is an antifungal component, it will have an antifungal effect; if the component (A) is an insect repellent component, it will have an insect repellent effect; if the component (A) is an antifouling component, it will have an antifouling effect; if the component (A) is an antislip component, it will have an antislip effect; if the component (A) is an antibacterial component, it will have an antibacterial effect; and if the component (A) is a virus inactivating component, it will have a virus inactivating effect. Furthermore, when two or more components are used as the active ingredient (A), the medicinal effects will depend on the type of component. For example, if the component (A) is a deodorizing component and an insect repellent component, it will have a deodorizing effect and an insect repellent effect.

[0029] The foamable medicinal effect-imparting composition of the present invention can be filled into a trigger- or pump-type spray container and used as a spray product, such as a propellant-free spray, or a propellant-containing aerosol, filled into a pressure-resistant container. The latter involves filling an aerosol concentrate into an aerosol container and pressurizing it with a propellant, including, but not limited to, liquefied petroleum gases (LPG) such as propane, normal butane, and isobutane; normal pentane, isopentane, dimethyl ether (DME), and hydrofluoroolefins such as HFO1234ze; and compressed gases such as nitrogen gas, carbon dioxide, nitrous oxide, and compressed air. The aerosol can also be converted into a metered-dose aerosol by providing a metered-dose valve. The blending ratio (volume ratio) of the aerosol concentrate to the propellant is preferably 10 / 90 to 60 / 40, more preferably 15 / 85 to 50 / 50, and even more preferably 20 / 80 to 40 / 60. The aerosol may be formulated as either an aqueous aerosol or an oil-based aerosol. The number, size, and shape of the nozzles in the spray or aerosol form are not particularly limited. The spray button may be any type that produces foam, but a spout type or one with a mechanical breakup mechanism is preferred.

[0030] The foamable medicinal effect-imparting composition of the present invention can be used to treat objects such as, but not limited to, toilet bowls, bathtubs, drain pipes, washing machine drums, window panes, air conditioner filters, aluminum fins of air conditioners, ventilation fans, screen doors, and automobiles. From the viewpoint of ease of treatment by spraying, the composition is suitable for use on toilet bowls, bathtubs, drain pipes, washing machine drums, and the like.

[0031] The present invention is not limited to the above-described embodiments, and various modifications are possible within the scope of the claims. Embodiments obtained by appropriately combining the technical means disclosed in different embodiments are also included in the technical scope of the present invention. The effects of the present invention will be explained in more detail below using examples, but the present invention is not limited to these examples. [Example]

[0032] [Preparation of Foaming Efficacy-Providing Composition] (A) Ingredients: Fragrance A (lavender fragrance containing 15% d-limonene, 15% linalyl acetate, and 10% linalool), d-limonene, and lavender oil; (B) Ingredients: Polyoxyethylene 2-ethylhexyl ether (hereinafter referred to as POE 2-ethylhexyl ether, Newcol 1008, manufactured by Nippon Nyukazai Co., Ltd.), alkyl polyglucoside (carbon number 10-16, Glucopon 600) A foamable medicinal composition was prepared by blending CSUP (manufactured by BASF), coconut oil alkyl dimethylamine oxide (Cadenax DMC-W, manufactured by Lion Specialty Chemicals Co., Ltd.), and (C) component (ethanol (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.), 2-phenoxyethanol (Dowanol EPh, manufactured by Ando Parachemie Co., Ltd.), and 1-phenoxy-2-propanol (Dowanol PPh, manufactured by Dow Chemical Japan Co., Ltd.) in the proportions (by mass) shown in Tables 1 and 2, and adding ion-exchanged water to make a total of 100% by mass. This foamable medicinal composition was placed in an aerosol container together with LPG as a propellant to prepare the aerosol products shown in Tables 1 and 2 (Examples 1 to 13). A button with a 0.6 mm inner diameter and 10 cm length and a resin pipe (product number D94WHCD "3"-A-NP-23-100N-W, manufactured by Mitani Valve Co., Ltd.) was used as the spray button. In addition, the temperature of each aerosol product was adjusted to 25°C in a water bath, and the base area was 11.3 cm 2 The foam was sprayed for 1 second into a 300 mL measuring cylinder, and the maximum foam volume X immediately after spraying and the foam volume Y 1 minute after spraying were read from the respective scales to determine the maximum volume X and volume Y, and the foam volume ratio (X / Y) was measured.

[0033] Similarly, a foamable medicinal effect imparting composition [L] was prepared by blending the (A) component (a lavender fragrance containing 15% d-limonene, 15% linalyl acetate, and 10% linalool) and the (B) component (POE 2-ethylhexyl ether (Newcol 1008, manufactured by Nippon Nyukazai Co., Ltd.) in the proportions (mass%) shown in Table 3, and adding ion-exchanged water to make a total of 100 mass%. This foamable medicinal effect imparting composition [L] was placed in an aerosol container together with a propellant [G] (volume ratio: [L] / [G] = 70 / 30), and the aerosol products shown in Table 3 were prepared. A resin pipe button (product number D94WHCD "3"-A-NP-23-100N-W, manufactured by Mitani Valve Co., Ltd.) with an inner diameter of 0.6 mm and a length of 10 cm was used as the spray button. The temperature of each aerosol product was adjusted to 25°C in a water bath, and the base area of ​​each product was 11.3 cm. 2 The foam was sprayed for 1 second into a 300 mL measuring cylinder, and the maximum foam volume X immediately after spraying and the foam volume Y 1 minute after spraying were read from the respective scales to determine the maximum volume X and volume Y, and the foam volume ratio (X / Y) was measured.

[0034] [Table 1]

[0035] [Table 2]

[0036] [Table 3]

[0037] [Efficacy Test 1 (Test results are shown in Table 4)] (1) Diffusion test of deodorizing fragrance ingredients 1. Two stainless steel tubes (20 cm in diameter, 85 cm in length) were connected together. One end of the tubes was covered with aluminum foil with a hole approximately 7 cm square in the center (hereafter referred to as the evaluation side). The other end was left uncovered (hereafter referred to as the sample side). 2. The sample was sprayed for 1 second into an open-topped glass petri dish (diameter 9.8 cm, height 1.8 cm), the sample was placed inside the cylinder from the sample side, and the sample was placed 10 cm from the end of the cylinder on the sample side. 3. The opening of the cylinder on the sample side was immediately covered with aluminum foil. 4. The evaluators continued to smell the scent in the tube from their mouths and measured the time it took for them to sense the scent after placing the glass dish in. The average measurement time was calculated by averaging the measurements taken by the 10 evaluators and was evaluated according to the following criteria. <Diffusion of deodorizing fragrance ingredients> ◎:(Average measurement time)≦12 seconds 〇:12 seconds<(average measurement time)≦17 seconds ×: 17 seconds <(average measurement time)

[0038] (2) Medicinal efficacy (deodorizing effect) test 1. Two stainless steel tubes (20 cm diameter, 85 cm length) were connected together. One end of the tube was covered with aluminum foil with an opening in the lower half (hereafter referred to as opening A) (hereafter referred to as the sample side), and the other end was covered with aluminum foil with a 7 cm x 7 cm opening in the center (hereafter referred to as opening B) (hereafter referred to as the evaluation side). In addition, a piece of aluminum foil large enough to cover opening B was attached to the evaluation side as a cover for opening B, and opening and closing this allowed opening and closing of opening B. 2. 0.5 mL of 1% ammonia water was placed on top of a glass stand (diameter 9.8 cm, height 1.8 cm), and placed inside the stainless steel cylinder from the sample side, 10 cm from the end of the cylinder on the sample side. In this state, a fan (Nidec Servo, VE55B5) was turned on and blew air for 10 seconds. 3. After 10 seconds, the fan was stopped, and the aluminum foil cover on opening B on the evaluation side was gently opened. The evaluator was asked to smell the inside of the tube through opening B and rate the ammonia odor on a 6-point scale (0: no odor, 1: barely detectable odor, 2: weak odor that is recognizable, 3: easily detectable odor, 4: strong odor, 5: intense odor) (the evaluation score was S). 4. Remove the glass base containing the foul odor from the sample side, then spray the sample onto an open-topped glass petri dish (diameter 9.8 cm, height 1.8 cm) for 1 second, place it inside from the sample side, place it 10 cm from the end of the sample side inside the cylinder, and leave it to stand for 10 seconds. 5. As in 3. above, the aluminum foil lid on opening B on the evaluation side was gently opened, and the evaluator was asked to smell the inside of the tube through opening B, and evaluate the ammonia odor on a 6-point scale (0: odorless, 1: barely detectable odor, 2: faint odor that is recognizable, 3: easily detectable odor, 4: strong odor, 5: intense odor) (the evaluation score was T). 6. The ammonia odor deodorizing rate was calculated by (ST) / S x 100. The results from 10 evaluators were averaged to calculate the average deodorizing rate, which was then evaluated according to the following criteria: <Medicinal efficacy (deodorizing fragrance effect) test> ◎: 60% or less (average deodorizing rate) 〇: 30%≦(average deodorizing rate)<60% ×: (Average deodorizing rate) <30%

[0039] (3) Foam performance test When various foaming medicinal compositions were sprayed onto a stainless steel plate, the foaming and popping (feel when used) were evaluated according to the following criteria. <Foaming and popping (usage sensation)> ◎: Good foaming and popping Good: The bubbles are hard to pop, or pop quickly and are hard to foam. ×: No bubbles pop at all

[0040] [Table 4]

[0041] As a result of the test, the base area was 11.3 cm 2 When sprayed for 1 second into a 300 mL measuring cylinder, Examples 1 to 13, in which the foam volume ratio (Y / X) was the ratio of the maximum foam volume X immediately after spraying to the foam volume Y 1 minute after spraying, were Y / X≦0.99, were excellent in terms of diffusibility of the deodorizing ingredient, deodorizing effect, and usability. Among these, Examples 2 to 8 and 11 to 13, in which Y / X≦0.70, were found to be more excellent in terms of diffusibility of the deodorizing ingredient, deodorizing effect, and usability. In contrast, Comparative Example 1, which did not satisfy Y / X≦0.99, did not achieve favorable results in terms of diffusibility of the deodorizing ingredient, deodorizing effect, and usability.

[0042] [Effectiveness test 2: Antifouling effect test] (1) Test Example 1 An aerosol product of Example 14 was obtained in the same manner as in Example 5, except that 0.05% by mass of a quaternary ammonium salt polymer compound, an antifouling component, was added instead of 0.05% by mass of fragrance A. The foaming medicinal effect-imparting composition of this aerosol product had a pH of 6.0 and a foam volume ratio (Y / X) of 0.27. The aerosol product of Example 14 was sprayed onto a toilet bowl for one second, left for one minute, and then flushed. Three drops of salad oil were added to the treated toilet bowl, and when water was flushed, the salad oil did not stick to the bowl and was completely flushed away.

[0043] (2) Test Example 2 An aerosol product of Example 15 was obtained in the same manner as in Example 11, except that 0.05% by mass of a quaternary ammonium salt polymer compound, an antifouling component, was added instead of 0.05% by mass of d-limonene in Example 12. The pH of the foamable medicinal composition of this aerosol product was 6.4, and the foam volume ratio (Y / X) was 0.08. The aerosol product of Example 15 was sprayed onto a toilet bowl for one second, left to stand for one minute, and then flushed. Three drops of salad oil were added to the treated toilet bowl, and when water was flushed, the salad oil did not stick to the bowl and was completely flushed away.

[0044] [Effectiveness test 3: Anti-mold effect test] (1) Test Example 1 An aerosol product of Example 16 was obtained in the same manner as in Example 5, except that 0.05% by mass of thymol, an antifungal component, was added instead of 0.05% by mass of fragrance A. The foamable medicinal effect-imparting composition of this aerosol product had a pH of 6.0 and a foam volume ratio (Y / X) of 0.23. The aerosol product of Example 16 was sprayed onto a bathroom tile for one second, left for one minute, then rinsed off with water. After leaving it for one week, no black mold or pink slime grew on the treated surface.

[0045] An aerosol product of Example 17 was obtained in the same manner as in Example 11, except that 0.05% by mass of thymol, an antifungal ingredient, was added instead of 0.05% by mass of fragrance A. The foamable medicinal effect-imparting composition of this aerosol product had a pH of 6.4 and a foam volume ratio (Y / X) of 0.09. The aerosol product of Example 17 was sprayed onto a bathroom tile for one second, left for one minute, then rinsed off with water. After leaving it for one week, no black mold or pink slime grew on the treated surface. [Industrial Applicability]

[0046] The foamable medicinal effect-imparting composition of the present invention can improve the diffusibility and medicinal effect of active ingredients such as deodorizing ingredients, antifouling ingredients, antifungal ingredients, antibacterial ingredients, and virus inactivating ingredients in toilet bowls, bathtubs, drain pipes, washing machine drums, window glass, air conditioner filters, aluminum fins of air conditioners, ventilation fans, screen doors, automobiles, etc., and therefore may be usable in spray products with these medicinal effects.

Claims

[Claim 1] 1. An effervescent medicinal composition for filling a spray product, comprising: The composition contains (A) an active ingredient, (B) a surfactant, (C) an organic solvent, and water, The composition was placed in a container with a base area of ​​11.3 cm ２ When the composition is sprayed for 1 second into a 300 mL measuring cylinder, the foam volume ratio, which is the ratio of the maximum foam volume X immediately after spraying to the foam volume Y 1 minute after spraying, is Y / X≦0.99.

Images